These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 15840407)
1. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Wang YX; da Cunha V; Martin-McNulty B; Vincelette J; Li W; Choy DF; Halks-Miller M; Mahmoudi M; Schroeder M; Johns A; Light DR; Dole WP Eur J Pharmacol; 2005 Apr; 512(2-3):215-22. PubMed ID: 15840407 [TBL] [Abstract][Full Text] [Related]
2. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Wang YX; Martin-McNulty B; da Cunha V; Vincelette J; Lu X; Feng Q; Halks-Miller M; Mahmoudi M; Schroeder M; Subramanyam B; Tseng JL; Deng GD; Schirm S; Johns A; Kauser K; Dole WP; Light DR Circulation; 2005 May; 111(17):2219-26. PubMed ID: 15851596 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-β1-TAK1. Li Q; Xu Y; Li X; Guo Y; Liu G Toxicol Lett; 2012 Jun; 211(2):91-7. PubMed ID: 22465603 [TBL] [Abstract][Full Text] [Related]
4. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. Kagiyama S; Matsumura K; Goto K; Otsubo T; Iida M Regul Pept; 2010 Feb; 160(1-3):133-9. PubMed ID: 19969025 [TBL] [Abstract][Full Text] [Related]
5. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Higashi M; Shimokawa H; Hattori T; Hiroki J; Mukai Y; Morikawa K; Ichiki T; Takahashi S; Takeshita A Circ Res; 2003 Oct; 93(8):767-75. PubMed ID: 14500337 [TBL] [Abstract][Full Text] [Related]
6. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Izumiya Y; Kim S; Izumi Y; Yoshida K; Yoshiyama M; Matsuzawa A; Ichijo H; Iwao H Circ Res; 2003 Oct; 93(9):874-83. PubMed ID: 14551246 [TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874 [TBL] [Abstract][Full Text] [Related]
8. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Balakumar P; Singh M Pharmacology; 2006; 78(2):91-7. PubMed ID: 16974135 [TBL] [Abstract][Full Text] [Related]
9. Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Kanda T; Hayashi K; Wakino S; Homma K; Yoshioka K; Hasegawa K; Sugano N; Tatematsu S; Takamatsu I; Mitsuhashi T; Saruta T Hypertension; 2005 Apr; 45(4):724-9. PubMed ID: 15699465 [TBL] [Abstract][Full Text] [Related]
10. Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats. Ho TJ; Huang CC; Huang CY; Lin WT Eur J Appl Physiol; 2012 Aug; 112(8):2943-55. PubMed ID: 22160250 [TBL] [Abstract][Full Text] [Related]
11. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Li Y; Kishimoto I; Saito Y; Harada M; Kuwahara K; Izumi T; Takahashi N; Kawakami R; Tanimoto K; Nakagawa Y; Nakanishi M; Adachi Y; Garbers DL; Fukamizu A; Nakao K Circulation; 2002 Sep; 106(13):1722-8. PubMed ID: 12270869 [TBL] [Abstract][Full Text] [Related]
12. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. Nishikimi T; Akimoto K; Wang X; Mori Y; Tadokoro K; Ishikawa Y; Shimokawa H; Ono H; Matsuoka H J Hypertens; 2004 Sep; 22(9):1787-96. PubMed ID: 15311108 [TBL] [Abstract][Full Text] [Related]
13. Rho kinase activation and gene expression related to vascular remodeling in normotensive rats with high angiotensin I converting enzyme levels. Rivera P; Ocaranza MP; Lavandero S; Jalil JE Hypertension; 2007 Oct; 50(4):792-8. PubMed ID: 17785632 [TBL] [Abstract][Full Text] [Related]
14. Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling. Ocaranza MP; Fierro C; Jalil JE; Moya J; Gonzalez L; Molina C; Mancilla C Clin Sci (Lond); 2018 Aug; 132(16):1837-1853. PubMed ID: 30065083 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. Nishikimi T; Koshikawa S; Ishikawa Y; Akimoto K; Inaba C; Ishimura K; Ono H; Matsuoka H J Hypertens; 2007 May; 25(5):1053-63. PubMed ID: 17414670 [TBL] [Abstract][Full Text] [Related]
16. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ Rho kinase pathways targeted to lipid rafts. Burger D; Montezano AC; Nishigaki N; He Y; Carter A; Touyz RM Arterioscler Thromb Vasc Biol; 2011 Aug; 31(8):1898-907. PubMed ID: 21597004 [TBL] [Abstract][Full Text] [Related]
17. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Li F; Xia W; Li A; Zhao C; Sun R Pharmacol Res; 2007 Jan; 55(1):64-71. PubMed ID: 17127075 [TBL] [Abstract][Full Text] [Related]
18. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Li P; Shibata R; Unno K; Shimano M; Furukawa M; Ohashi T; Cheng X; Nagata K; Ouchi N; Murohara T Hypertension; 2010 Jan; 55(1):69-75. PubMed ID: 19933924 [TBL] [Abstract][Full Text] [Related]